登录 | 注册    关注公众号  
微信公众号
搜索
 >  Cell>ASGR1 >CHEK-ATP080

HEK293/Human ASGR1 Stable Cell Line

For research use only.

描述(Description)

HEK293/Human ASGR1 Stable Cell Line

应用说明(Application)

Binding assay by FACS and cell based ELISA.

生长特性(Growth Properties)

Adherent

筛选标记(Selection Marker)

Hygromycin B (200 μg/mL)

培养基(Culture Medium)

DMEM medium + 10% FBS

冻存液(Freeze Medium)

10% DMSO + 90% FBS

装量(Quantity)

1 vial contains at least 5x10^6 cells in 1 ml of 10% DMSO in FBS.

存储(Storage)

Frozen in liquid nitrogen.

支原体检测(Mycoplasma Testing)

Negative

无菌检测(Sterility Testing)

Negative

使用说明(Instructions for Use)

See data sheet for detailed culturing and assay protocol.

 

活性(Bioactivity)

ASGR1 FACS

Fig. FACS analysis of ASGR1 on HEK293/Human ASGR1 Stable Cell Line.
FACS assay shows that Anti-ASGR1 Antibody can bind to HEK293/Human ASGR1 Stable Cell Line. HEK293/Human ASGR1 Stable Cell Line was red line, Negative control HEK293 cells was grey line (QC tested).

Protocol

如有相关细胞池需求请联系我们

 

背景(Background)

ASGPR, a transmembrane C-type lectin, recognizes a wide variety of ligands that contain either terminal galactose (Gal) or N-acetylgalactosamine (GalNAc) residues and has been identified as a highly selective receptor on hepatocytes. The ASGR is composed of both a major (ASGR1) and minor subunit (ASGR2). ASGR1 has been shown to be efficiently targeted to the plasma membrane and to undergo constitutive endocytosis and recycling and found mainly expressed in the human liver.

 

License Disclosure

This cell line is provided for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit modification of this cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license. Modifications of this cell line, transfer to another facility, or commercial use of the cell lines may require a separate license and additional fees. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
ASGR1靶点信息
英文全称:Asialoglycoprotein receptor 1
中文全称:去唾液酸糖蛋白受体-1
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:0详情
最高研发阶段:临床前
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定